PetVivo Holdings Inc PETV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PETV is a good fit for your portfolio.
News
-
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA
-
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN NAPLES FLORIDA
-
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN CHARLESTON, SOUTH CAROLINA
-
SmallCapVoice.com Inc. (“SCV”) to Host First Annual Safety Summit featuring Up-and-Coming Public Companies
-
Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer
-
New to The Street Announces its Five Corporate TV Interviews, Airing Episode 561 on the FOX Business Network Monday, March 11, 2024, at 10:30 PM PT
-
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
-
PetVivo Holdings, Inc. Commences Trading on Upstream Under PETV
Trading Information
- Previous Close Price
- $0.80
- Day Range
- $0.77–0.80
- 52-Week Range
- $0.33–2.90
- Bid/Ask
- $0.77 / $0.82
- Market Cap
- $13.16 Mil
- Volume/Avg
- 2,350 / 54,015
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 25
- Website
- https://www.petvivo.com
Valuation
|
Metric
|
PETV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 13.14 |
Price/Sales | 9.36 |
Price/Cash Flow | — |
Price/Earnings
PETV
Financial Strength
|
Metric
|
PETV
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 0.90 |
Interest Coverage | −2,340.16 |
Quick Ratio
PETV
Profitability
|
Metric
|
PETV
|
|---|---|
Return on Assets (Normalized) | −238.43% |
Return on Equity (Normalized) | −993.53% |
Return on Invested Capital (Normalized) | −439.79% |
Return on Assets
PETV
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Drvxqsrh | Dttvd | $185.4 Bil | |
SYK
| Stryker Corp | Qvhtvjgkn | Mmn | $128.2 Bil | |
BSX
| Boston Scientific Corp | Jrslggpx | Ssygjnd | $107.7 Bil | |
MDT
| Medtronic PLC | Tvcyysjpk | Tdvxc | $105.2 Bil | |
DXCM
| DexCom Inc | Lpbxlfvlg | Lbmy | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Dbfqtkldc | Srmsrzl | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Mxljcjxzq | Xsmql | $24.6 Bil | |
ALGN
| Align Technology Inc | Bztnmtxj | Nylqg | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Ktylfmpx | Qtbvfrk | $18.7 Bil | |
PODD
| Insulet Corp | Zcpxbxbdz | Ypybcys | $11.5 Bil |